Results of the study with the blood test Epi proColon® is now published in the journal of “Cancer Treatment and Research Communications” . Epigenomics AG announced that the results of the ADMIT study confirm that a blood-based colorectal cancer screening test has the potential to increase the participation in colorectal cancer screening compared to a fecal test.
MPLN’s Nicholas Potter and Geneuity’s Neil Quigley are co-authors on the recent paper in cancer treatment and research communications concerning colorectal cancer screening programs. This study compares uptake of an experimental blood test (Epi proColon IVD) with that of a FIT for colorectal cancer screening in an office setting. Dr. Potter provided study design, analysis, interpretation of data and statistical analysis. Dr. Quigley was the site principal investigator, providing study supervision and data acquisition. Additionally Geneuity’s Donald Henley, Kara Whitlock and Daniel Thomas provided technical assistance for the study.
Liles E.G, Coronado G.D, Perrin N, Howell Harte A, Nungesser R, Quigley N, Potter N.T, Weiss G, Koenig T, deVos T (2017) Uptake of a colorectal cancer screening blood test is higher than of a fecal test offered in clinic: A randomized trial Cancer Treatment and Research Communications. 10: 27–31
Geneuity a subsidiary of Molecular Pathology Laboratory Network Inc. launches Ventana PD-L1 and PD-1 assays, expanding their oncology immunohistochemistry menu of tests for NSCLC and other tumor types. MPLN’s repertoire of integrated testing now includes the addition of two new immunohistochemistry markers: VENTANA PD-L1 (SP263) Rabbit Monoclonal Primary Antibody and VENTANA PD-1 (NAT105) Mouse Monoclonal Antibody.
PD-L1 by immunohistochemistry is indicated as an aid in the assessment of PD-L1 expression in non-small cell lung cancer (NSCLC) and other tumor types. Assessment of tumor PD-L1 protein levels may have prognostic and/or therapeutic significance in some cancer patients. Specifically, identifying PD-L1 expression on tumor cells may help determine which patients will most benefit from anti-PD-1/PD-L1 therapy.
The VENTANA PD-L1 (SP263) Rabbit Monoclonal Primary Antibody (VENTANA PD-L1 (SP263)) is a rabbit monoclonal primary antibody directed against the programmed deathligand1 (PD-L1) B7 homolog 1 (B7-H1, CD274). The antibody detects the extracellular domain of PD-L1 and produces membranous and/or cytoplasmic staining.
PD-1 by immunohistochemistry detects the immune regulatory molecule programmed death-1 (PD-1) and has utility in both hematopathology diagnostics and in cancer biology. The programmed death-1 (PD-1) protein is expressed by follicular helper T-cells, and is useful in the diagnosis of hematolymphoid malignancies such as angioimmunoblastic T-cell lymphoma (AITL). In addition, clinical evidence suggests that IHC staining of the PD-1/PD-L1 pathway may have prognostic and/or therapeutic significance in some cancer patients.
MPLN selected the Ventana SP263 antibody as it complements existing laboratory platform and automation and has a simple single numerical cutoff value making interpretation more robust.
MPLN LIS Blue v7.1.0 Ocean
Launch date June 20, 2016
Our next-generation laboratory information system (LIS) has been developed from the ground up to be fast, easy to use, accessible, and secure. MPLN has implemented the latest web technology to develop LIS Blue as a globally accessible browser-based web application.
LIS Blue delivers the same primary functionality as MPLN’s Indigo LIS. You can order tests, view reports, and check pending lists. The new interface is familiar and intuitive for those currently using MPLN’s Indigo LIS.
What makes it better?
Speed / Usability / Accessibility / Data Security
How do I start using it?
First, you will need a username and password. If you already have an account with MPLN Indigo LIS, it will carry over to the new system. If you require setting up a new account, contact client services at 865 380 9746
Next, you will need a modern desktop web browser. We recommend using the latest version of Google Chrome.
Access LIS Blue:
What else do I need to know?
MPLN’s Indigo LIS will no longer be available once LIS Blue is live, and we want to make the transition as easy as possible for our valued customers. Our client service and technical support departments are available to help and have been working hard to make sure everyone is ready to make the switch.
Call client services or visit our help documentation for more info:
865 380 9746
MARYVILLE, Tenn. – (Sept 17, 2015) – Geneuity and Molecular Pathology Laboratory Network (MPLN) today announced that it is expanding its integrated oncology specialty testing offering to include Next Generation Sequencing assays for solid tumor. The new panels will address Lung, Colon, Melanoma and an unknown primary 8 gene panel with soon to be released Gastrointestinal Stroma, Glioma, Ovarian, Renal and Thyroid solid tumor panels. Geneuity will be making the QIAGEN Human Tumor Actionable Mutations Panel available for clinical trial studies.
Dr. Jamie Platt, Vice President of Genomic Solutions at Geneuity and Molecular Pathology Laboratory Network, Inc., evaluated the illumina TruSight® Tumor 15 and said the panel’s simplicity and ease of use makes it well-suited for translational labs, “The value and appeal of next-generation sequencing is the potential to consolidate traditionally iterative tumor analyses. Our evaluation of the new TruSight Tumor 15, with its streamlined library prep and sequencing workflow, gives us confidence that this application is ideal for deployment. Even our most challenging samples produced results, including those with low nucleic acid inputs, giving us assurance we can analyze our most precious specimens.”
Read illumina’s press release on Business Wire
Maryville, Tennessee – (July 15, 2015) – (Business Wire). Geneuity today announced that it is expanding early access to Thermo Fisher Scientific’s targeted, next generation sequencing (NGS) technology and Oncomine Focus Assay for services it plans to offer to its broad pharmaceutical customer base.
Geneuity CRS and Molecular Pathology Laboratory Network Inc. Vice President Genomic Solutions Jamie Platt Ph.D., will be presenting at San Diego illumina Medical Genomics Summit June 8th 2015. Dr. Platt will present “LDTs to NGS IVD Systems, a Customers Perspective” and discuss verification of the first FDA IVD use cleared MiSeqDx Next Generation Sequencing system. Dr. Platt will also highlight differences between Laboratory Developed Tests (LDT) and IVD assays in a CLIA environment and share experiences with the illumina IVD assay Cystic Fibrosis 139-Variant Assay (IVD).
Geneuity CRS and Molecular Pathology Laboratory Network Inc. Vice President Genomic Solutions Jamie Platt Ph.D., will be presenting at Biomarkers & Diagnostics World Congress 2015 in Philadelphia PA. May 7th . Dr. Platt will present on ‘Opportunities and Challenges for NGS-Based Clinical Trials’. Key challenges in NGS-based clinical trials will be discussed, and opportunities around assay validation, companion diagnostics, data analysis, genomic annotation and supporting services will be highlighted.
Maryville, Tennessee based Molecular Pathology Laboratory Network, Inc. (MPLN) acquires the Illumina MiSeqDx™ next generation sequencing system to expand its portfolio of molecular testing and clinical research services to support growing demand in personalized medicine. Continue Reading…
MPLN, through it’s Geneuity Clinical Research Services Division, participated in the instrument performance evaluations that contributed to the FDA approval of the Panther(TM) system for use with the APTIMA 2 Combo assay, particularly testing for the common sexually transmitted infections Chlamydia trachomatis andNeisseria gonorrhoeae. “It is a credit to the scores of talented and dedicated scientists and engineers who made it happen. We believe that PANTHER will continue that revolution by bringing the power of fully-automated, sample to result capabilities to low- and medium- volume labs.,” said Carl Hull, Gene-Probe’s chairman and chief executive officer.